India's Pharma & MedTech Boom Signals Shift to Self-Reliant Healthcare Growth

Union Minister Jitendra Singh stated that India is transforming into a robust pharma economy, moving from an import-dependent healthcare system to one driven by indigenous capabilities. He highlighted that this shift, marked by developing domestic antibiotics, vaccines, and advanced therapies, positions India as a key global hub for affordable solutions. Singh pointed to policy initiatives like the Rs 5,000 crore PRIP scheme and the MedTech Mitra platform to fuel innovation and streamline regulations. The government aims to significantly expand India's share of the global medical device market beyond its current 1.5% under the National Medical Device Policy 2023.

Key Points: India's Pharma, MedTech Boom Towards Self-Reliant Healthcare

  • Shift from import-dependent to indigenous healthcare
  • Growth into a global hub for affordable solutions
  • Policy push with PRIP & MedTech Mitra schemes
  • Aim to expand global medical device market share
2 min read

India's MedTech, Pharma boom sign of shift to self-reliant healthcare growth: Jitendra Singh

Union Minister Jitendra Singh highlights India's shift from import dependence to indigenous innovation in pharma and medical technology, boosting GDP.

"Today, India is developing its own antibiotics, vaccines, and advanced therapies, marking a decisive shift towards self-reliance. - Jitendra Singh"

New Delhi, March 22

Union Minister of State for Science and Technology, Jitendra Singh, stated that India is steadily evolving into a robust pharma economy. He noted that this transformation will accelerate future growth and emerge as a significant contributor to the country's overall GDP.

The minister emphasized that the growing strength of India's pharmaceutical and medtech manufacturing ecosystem positions the country as a key global hub for affordable healthcare solutions.

Delivering a keynote address at a healthcare summit in New Delhi on Saturday, Singh explained that the national healthcare ecosystem is undergoing a major shift. According to the Minister, this transition focuses on global quality benchmarks and the integration of research with industry.

Singh highlighted that over the past decade, India witnessed a "remarkable transformation in healthcare, moving from a largely import-dependent system to one driven by indigenous capabilities."

The Minister recalled a time when critical medical devices, implants, and advanced drugs were largely sourced from abroad. This reliance made treatment expensive and inaccessible for many citizens.

"Today, India is developing its own antibiotics, vaccines, and advanced therapies, marking a decisive shift towards self-reliance," Singh said. He referred to the rapid progress made during the COVID-19 pandemic as a turning point where India supplied vaccines to several countries, reinforcing its role as a global healthcare partner.

The narrative of the sector now includes cutting-edge technologies such as gene therapy and innovations for diseases like sickle cell anemia. Singh noted that Indian institutions now contribute to globally recognized research.

He further highlighted that "homegrown" products match global benchmarks, with regulatory systems aligned to international standards. Through streamlined approval mechanisms, indigenous medical devices such as stents and ventilators are ensuring safety and affordability.

On the policy front, Singh pointed to the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme, which has an outlay of Rs 5,000 crore. This initiative aims to transition India from low-cost manufacturing to high-value innovation.

He also mentioned that the MedTech Mitra platform is enabling innovators to navigate regulatory pathways more efficiently.

Currently, India holds approximately 1.5 per cent of the global medical device market. However, Singh stated that the government is working to significantly expand this share under the National Medical Device Policy 2023.

He stated that the collaboration between industry, academia, and government institutions has been institutionalized to ensure India becomes a preferred global destination for high-quality healthcare.

- ANI

Share this article:

Reader Comments

P
Priya S
While the intent is good, I hope this 'self-reliance' also translates to better accessibility in rural areas. We have great hospitals in metros, but what about primary healthcare in villages? The focus should be on making these affordable innovations reach the last mile.
R
Rohit P
The COVID vaccine mission was a real eye-opener for the world. When others were struggling, India was not only vaccinating its own but also helping other nations. That's the power of a strong pharma base. Excited to see us moving into gene therapy and advanced research now.
M
Michael C
As someone working in global health, India's role as a supplier of affordable medicines is crucial. If they can maintain quality while scaling up medtech innovation, it will benefit patients worldwide. The PRIP scheme's focus on high-value R&D is the right direction.
S
Shreya B
Hope the quality control is as robust as they claim. We've seen issues with some generic drugs in the past. Matching global benchmarks is one thing, but consistently maintaining them is the real challenge. The MedTech Mitra platform sounds promising for startups though.
K
Karthik V
From 1.5% to...? They didn't mention a target. The National Medical Device Policy needs clear, ambitious goals. We have the talent and the market. With the right policy push and industry-academia collaboration, we can definitely be among the top five global players. Jai Hind!

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50